Effects of Zoledronate on Mortality and Morbidity afterSurgical Treatment of Hip Fractures

We aimed to evaluate the effects of intertrochanteric femoral fractures on mortality, morbidity, and cost of zoledronate treatmentin elderly patients treated by osteosynthesis. Based on Evans classification, 114 patients with unstable intertrochanteric femoralfractures were treated with osteosynthesis. After the surgical treatment of intertrochanteric fractures, the treatment group (M/F,24/32; mean age, 76.7±SD years) received zoledronate infusion, and the control group (M/F, 20/38; mean age, 80.2±SD years)received placebo. Postoperative control visits were performed at 6-week, 3-month, 6-month, and 12-month time points. Functionallevel of patients was evaluated by the modified Harris hip score and Merle d’Aubign ́e hip score. By 12 months, the mean HHSin treatment and control groups was 81.93 and 72.9, respectively. For time of death of the patients, mortality was found to be57.1% (16/28) on the first 3 months and 92.9% (26/28) on the first six months. The mortality rate in the treatment and controlgroups was 14.3% (8/56) and 34.5% (20/58), respectively. The use of zoledronic acid after surgical treatment of intertrochantericfemoral fractures in osteoporotic elderly patients is a safe treatment modality which helps to reduce mortality, improves functionaloutcomes, and has less side effects with single dose use per year